Compare MPLT & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPLT | TROX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | 133 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2012 |
| Metric | MPLT | TROX |
|---|---|---|
| Price | $37.09 | $6.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $32.67 | $6.36 |
| AVG Volume (30 Days) | 437.1K | ★ 2.5M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,898,000,000.00 |
| Revenue This Year | N/A | $6.94 |
| Revenue Next Year | N/A | $5.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.24 | $2.86 |
| 52 Week High | $37.61 | $10.59 |
| Indicator | MPLT | TROX |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 32.38 |
| Support Level | $26.20 | $6.13 |
| Resistance Level | N/A | $6.96 |
| Average True Range (ATR) | 2.49 | 0.47 |
| MACD | 0.84 | -0.07 |
| Stochastic Oscillator | 95.22 | 4.02 |
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.